Causality assessment of suspected drug induced liver injury (�ILI) and herb induced liver injury (HILI) is hampered by the lack of a standardized approach to be used by attending physicians and at various subsequent evaluating levels. The aim of this review was to analyze the suitability of the liver specific Council for International Organizations of �edical Sciences (CIO�S) scale as a standard tool for causality assessment in �ILI and HILI cases. �ub�ed database was searched for the following terms: drug induced liver injury; herb induced liver injury; �ILI causality assessment; and HILI causality assessment. The strength of the CIO�S lies in its potential as a standardized scale for �ILI and HILI causality assessment. Other advantages include its liver specificity and its validation for hepatotoxicity with excellent sensitivity, specificity and predictive validity, based on cases with a positive reexposure test. This scale allows prospective collection of all relevant data required for a valid causality assessment. It does not require expert knowledge in hepatotoxicity and its results may subsequently be refined. Weaknesses of the CIO�S scale include the limited exclusion of alternative causes and qualitatively graded risk factors. In conclusion, CIO�S appears to be suitable as a standard scale for attending physicians, regulatory agencies, expert panels and other scientists to provide a standardized, reproducible causality assessment in suspected �ILI and HILI cases, applicable primarily at all assessing levels involved.
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tool for all involved parties will allow early and prospective collection of all relevant data required for a valid causality assessment in clinical hepatology.
INTRODUCTION
Drug induced liver injury (DILI) and herb induced liver injury (HILI) are complex diseases and often overdiagnosed [1] [2] [3] [4] [5] . An expert review of suspected DILI reports from primary and secondary care physicians to the UK Committee on the Safety of Medicine revealed that 47.1% of the cases were not DILI and that the misdiagnoses delayed arriving at the correct diagnoses, possibly worsening patient outcome [1] . Misdiagnosis was a common phenomenon in other DILI studies [2] [3] [4] , including publications in which DILI was initially assumed, but hepatitis E virus infection later on evolved as the correct diagnosis [2, 3] . Similarly, in a recent assessment of initially suspected HILI, correct diagnoses were missed in 278/573 cases, corresponding to 48.5% [5] . Given these frequencies because of insufficient case assessment, DILI and HILI represent major issues for physicians who care for patients with these diseases.
Physicians commonly are confronted with a wealth of published data about hepatic adverse drug and herb reactions and may use this information for evaluating the cases of their patients. Reviews addressed general aspects of DILI [6, 7] or HILI [4, [8] [9] [10] , whereas other reports focused on various basic features like clinical course, prognosis, alternative causes, case definition and phenotype standardization [5, [11] [12] [13] [14] [15] [16] [17] . They suggest a similar or identical clinical presentation of DILI and HILI, raising the question of whether HILI needs a separate term. However, major differences exist between DILI and HILI; DILI is caused by a single chemically characterized drug, whereas HILI is triggered by a chemical mixture constituted of the herbal extract, which often lacks the benefit of regulatory surveillance. Herbal product quality varies and is a major issue in HILI, adding to the complexity in evaluating causality for herbs. This may explain why HILI is considered as a poorly defined entity, is a neglected disease, and requires special attention.
Potential genetic risk factors and biomarkers, including micro-RNA, are presently being investigated to explain DILI and HILI disease [18] [19] [20] . These data provide promising clinical and scientific results but currently contribute little to diagnose DILI or HILI correctly and in time, or to exclude alternative causes. Recognizing that the best approach is still not available in clinical practice, the physician needs a pragmatic guideline to quickly evaluate suspicious cases and reach a conclusive diagnosis. This is at present best achieved by the combination of clinical judgement and a liver specific causality assessment algorithm like the CIOMS (Council for International Organizations of Medical Sciences) scale [21, 22] , as has been summarized recently [10, 14, [23] [24] [25] . For DILI and HILI case reports, the CIOMS scale based on international consensus meetings [21, 22, 26, 27] is the commonly applied method to assess causality [4, 5, 10, 14, 23, 24, 28, 29] . In clinical practice, causality assessment of suspected hepatotoxicity is hampered by the lack of a standardized approach, which is applicable to all levels of causality assessment [4, 14, 24] and requires simplicity of the assessment method rather than complexity to evaluate DILI and HILI cases.
This review analyzes the suitability of the liver specific CIOMS scale for causality assessment in DILI and HILI cases as a standard for attending physicians, regulatory agencies, expert panels and the scientific community. It focuses on the characteristic features of the CIOMS scale, discusses strengths and weaknesses, and suggests approaches for the clinician who lacks a standby panel of DILI or HILI experts.
The PubMed database was searched for the following terms: drug induced liver injury; herb induced liver injury; DILI causality assessment; and HILI causality assessment. The literature search was done on June 4, 2013. Several hundreds of records were initially obtained, depending of the term used. The first 50 publications of each search were analyzed in depth for suitability in the analysis of the CIOMS scale quality, with numerous duplicated reports found in each category. The final compilation of evaluated publications consists of original papers, case series, case reports, consensus reports and review articles. All relevant reports were included in the reference list to be presented in this review. Analyzed reports were published between 1977 and 2013, preferentially within the last decade.
GENERAL ASPECTS
The liver specific and quantitative CIOMS scale was conceptualized and developed in consensus meetings organized at the request of the Council for International Organizations of Medical Sciences (CIOMS), with details published in 1993 [21, 22] . This CIOMS scale represented a breakthrough in DILI causality assessment methods and extended, specified and quantified the preceding qualitative RUCAM (Roussel Uclaf Causality Assessment Method) of 1988 [26] and qualitative CIOMS method of 1990 [27] . The basis for the CIOMS scale was provided by eight experts in hepatology from 6 countries and included J P Benhamou (France), J Bircher (Germany), G Danan (France), W C Maddrey (United States), J Neuberger (United Kingdom), F Orlandi (Italy), N Tygstrup (Denmark) and H J Zimmerman (United States) [21] . This expert panel evaluated DILI cases for case characteris-tics, hepatotoxicity criteria, liver injury pattern and reexposure criteria, standardized DILI case assessment with specific, quantitative items [21] , and the experts validated their method with established positive reexposure DILI case results [22] . The CIOMS scale was developed for assessment of a single drug containing a synthetic product and may be used for a single herb containing multiple chemical constituents, but does not allow causality attribution to a specific constituent. The scale is a learning system and not immutable; room for improvement and refinement of the CIOMS scale has been outlined [29] , with modifications of the CIOMS scale based on improved diagnostic instruments [14] .
STRENGTHS

Prospective use
Its prospective application enables the CIOMS scale to provide an early causality grading for patients with suspected DILI or HILI; its results can be adapted further to diagnostic and therapeutic measures. This scale is easily used as a bedside tool at a time the disease is developing (Tables 1 and 2) . Results do not depend on expert opinion and are quickly available for trained physicians to decide whether DILI and/or HILI should be considered as relevant differential diagnoses due to their clinical experience. Assessment is best started on the day of suspecting DILI or HILI, with a continuous update of the required data and a change in the diagnostic and therapeutic concept if needed. Finally, a complete data set for presentation to regulatory agencies, expert panels and eventually for publication is obtained [24, [30] [31] [32] [33] , including a checklist with additional data helpful in overall case evaluation and causality assessment (Table 3) . Therefore, the CIOMS scale should be considered as a standard for causality assessment of DILI and HILI, both for the attending physician and later evaluation stages. Using one single assessment method at all evaluating levels allows comparison of different assessment outcomes.
Liver specificity
Liver specificity is a hallmark of the CIOMS scale, in contrast to liver unspecific causality assessment methods or ad hoc approaches [4, 24] . The CIOMS items are specially tailored to liver injury and not applicable to liver unrelated adverse drug reactions [24] . All current core elements of hepatotoxicity are considered in the CIOMS scale (Tables 1 and 2 ): time to onset of increased liver values or symptoms from the beginning and cessation of the drug/herb; course of liver enzymes after cessation; risk factors such as alcohol, age and pregnancy; comedication with other drugs/herbs; search for alternative causes, previously known drug/herb hepatotoxicity; and response to unintentional reexposure [21] [22] [23] [24] [25] based on specific criteria (Table 4) . The individual items are transparent and facilitate quick and precise answers.
The CIOMS scale is structured and all its items undergo quantitative rather than qualitative assessment and scoring (Tables 1 and 2) [4, 5, 10, 14, 21, 23, 24, 29] . Each item is weighted with specific scores based on the answer. The sum of the individual scores gives a final score that may range from -9 to +14 points, allowing for sufficient discrimination. The final score provides causality levels for the individual synthetic drug or herb as highly probable, probable, possible, unlikely or excluded (Tables 1 and 2) [12, 24, [30] [31] [32] .
Hepatotoxicity definition
The international CIOMS expert panel defined liver injury in its consensus report as increased alanine aminotransferase (ALT) and/or alkaline phosphatase (ALP) activities of at least 2N, with N as the upper limit of normal [21] . Conversely, the consensus of the international DILI Expert Working Group with participants from Europe, the United States and Japan raised the ALT cut off point to 5N or 3N if total bilirubin values exceeded 2N and considered the 2N of ALP as an appropriate definition criterion [14] . Whereas the DILI Expert Working Group recommendations were based on expert opinion alone [14] , those of the CIOMS expert panel were derived from both expert opinion and assessment of reference reexposure DILI cases [21, 22] . Raising the ALT cut off to 5N increases the specificity of the hepatotoxicity causality assessment [24] , eliminates false positive cases and substantiates hepatotoxicity causality at a higher level of probability [16, 24] . The lower threshold of ALT > 2N will include multiple cases with nonspecific enzyme increases and requires more stringent exclusion of causes unrelated to drug(s) and herb(s) [24] . Also for low threshold N values, the inclusion rate of alternative diagnoses must be higher; false positive fulfilment of a hepatotoxicity definition results in high numbers of misattributed cases due to overdiagnosing and overreporting [8, 12, 17, 24, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . This phenomenon is illustrated in a recent HILI study where initial ALT values were available in only 8/22 cases (36%), including 3 cases with a range of 50-69 U/L serum activity [36] . None withstanding, regulatory assessment attributed a possible causality for the incriminated herb to all 22 cases [36, 42] . In other spontaneous case collections, initial ALT values were available in 5/24 cases (21%) [35] , 19/22 cases (86%) [37] , 12/15 cases (80%) [38] , and 7/13 cases (54%) [39] . The corresponding figures for ALT in published case reports of HILI were 16/16 cases (100%) [35] , 21/21 cases (100%) [32] , and 5/8 cases (63%) [33] . ALT values were included in DILI reports for amoxicillin/clavulanic acid, troglitazone, pioglitazone and montelukast in 11% to 88% of the cases, which were not further scored for causality by the Drug Induced Liver Injury Network (DILIN) [6] . ALT underreporting is therefore an issue for both DILI and HILI.
Other arguments merit further considerations. An ALT cut off point of 5N may not be applicable to some types of chronic liver injury like methotrexate liver fibrosis or nodular regenerative hyperplasia; misinterpretation is also possible in some forms of acute liver injury by mitochondrial toxicity in cases of valproate or fialuridine hepatotoxicity [14] . Aspartate aminotransferase (AST) activities may be used instead if ALT activities are unavailable [14, 44, 45] and other pathologies for AST increases are excluded [14] . ALP increases should be paral-The CIOMS scale is based on the original CIOMS scale [21] and was adapted from previous modifications [4, 14, 23, 24, 44, 45] . The above items specifically refer to the hepatocellular type of injury rather than to the cholestatic or mixed type (shown in Table 2 ). Regarding risk factor of alcohol use, 1 drink commonly contains about 10 g ethanol and details were discussed recently [14, 44, 45] . leled by γ-glutamyltranspeptidase (γGT) to rule out isolated increases of ALP activities due to bone rather than hepatobiliary disease. However, γGT alone is not an appropriate parameter for liver cell injury [14, 36] , contrary to published claims [42] . In addition, isolated hyperbilirubinemia is not DILI or HILI specific and may be caused by Gilbert's syndrome [1, 14] .
Liver injury pattern
The CIOMS scale takes into account divergent laboratory constellations of the liver injury pattern in the hepatocellular and the cholestatic type of liver injury and The CIOMS scale presented in this table is designed specifically for the cholestatic or mixed type of liver injury rather than for the hepatocellular type, which differs in a few items and is presented separately in Table 1 . Additional details and abbreviations are provided in the legend of Table 1 . Abbreviation: ALP, Alkaline phosphatase. Total score with resulting causality grading: ≤ 0, excluded; 1-2, unlikely; 3-5, possible; 6-8, probable; ≥ 9, highly probable. therefore provides two different subscales [21, 23, 24] for the hepatocellular type of injury (Table 1 ) and for the cholestatic or mixed type (Table 2) . These types are differentiated by the ratio R, calculated as the ALT/ALP activity measured at the time liver injury is suspected, with both activities expressed as multiples of N [21, 24] . Injury is hepatocellular, if only ALT > 2N, alternatively if R ≥ 5; cholestatic injury is assumed, if only ALP > 2N or R ≤ 2; mixed damage is prevalent, if ALT > 2N and ALP is increased, with R > 2 and R < 5 [21, 23, 24] . Of note, R may vary during the later course of the liver injury independent from the initial attribution of damage type.
Time to onset from the beginning of the drug/herb
Clear challenge criteria are defined with a time frame between beginning of the drug/herb use as the first day of intake and the onset of increased liver enzymes or symptoms at the time of ongoing use, with a high score for 5-90 d and a lower one for < 5 d or > 90 d (Tables  1 and 2) . If drug/herb use has been terminated prior to the onset of challenge criteria, then this specific condition must be considered and scored exclusively. Scoring is only possible when the onset occurs within 15 d after cessation for the hepatocellular injury (Table 1) or 30 d  for the cholestatic or mixed type (Table 2) , a longer interval commonly excludes causality (Tables 1 and 2 ). An exemption is provided for slowly metabolized chemicals like amiodarone, leflunomide and clavulanate [44, 45] ; no definitive time frame can be provided in these cases due to varying half lives. The time frame of challenge and latency period were neither specified nor individually scored by other causality assessment methods [4, 24] , including the DILIN method [49, 50] .
Course of liver enzymes after cessation of the drug/herb
Precise dechallenge criteria are cornerstones of the CI-OMS scale and facilitate causality assessment (Tables 1  and 2 ). In analogy to the periods mentioned, the physician can easily determine relevant future time points for repeated liver enzyme tests. When dechallenge data are missing in retrospective analyses, the CIOMS scale considers this and provides 0, but not negative points, so 
Conditions and criteria for an unintentional reexposure test are described in previous reports [4, 21, 22, 24, 26, 27] . Accordingly, required data for the hepaAccordingly, required data for the hepatocellular type of liver injury are the ALT levels just before reexposure, designed as baseline ALT or ALTb, and the ALT levels during reexposure, designed as ALTr. Response to reexposure is positive, if both criteria are met: first, ALTb is below 5N with N as the upper limit of the normal value, and second ALTr ≥ 2ALTb. Other variations lead to negative or uninterpretable results. For the cholestatic or mixed type of liver injury, correFor the cholestatic or mixed type of liver injury, corresponding values of ALP are to be used rather than of ALT. ALP: Alkaline ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; NA: Not available.
that the overall score may still present a probable causality level. Of note, the dechallenge time frame was not specifically considered or scored by the DILIN method [49, 50] or by virtually any of the other methods [4, 24] .
Risk factors
The consensus report of the international CIOMS expert panel considered alcohol and age ≥ 55 years as risk factors each scoring +1 point (Tables 1 and 2 ) [21] , as suggested by DILI cases with positive reexposure [21, 22] . The international DILI Expert Working Group specified alcohol intake of > 2 drinks per day (> 14 units/week) in women and > 3 drinks per day (21 units/week) in men as the lower threshold for alcohol intake as a risk factor (Tables 1 and 2 ) [14] . This limit is in line with the recommendations of NIH LiverTox equalling 1 drink to 10 g ethanol [44, 45] . The impact of including alcohol as a risk factor on the overall CIOMS scoring was negligible as only 9/146 patients (6%) of a HILI study cohort were allotted an alcohol related scoring point (Table 5 ) [12, 30, 32, [36] [37] [38] [39] [46] [47] [48] . In these 9 patients, CIOMS causality grading was changed in only one case (patient 16) and unchanged in the other 8 cases (patients 2, 13, 14, 17, 20, 21, 22, 32) ( Table 6 ). In the single case (patient 16), alcohol as risk factor raised the overall CIOMS scoring from 0 to +01 point, i.e., from excluded to unlikely causality (Table 6 ). Therefore, alcohol per se as risk factor upgrades the CIOMS causality level in virtually none of the cases in this study cohort.
Age ≥ 55 years was as a risk factor in 44/146 cases (30%) of the analyzed HILI study cohort (Table 5 ) [12, 30, 32, [36] [37] [38] [39] [46] [47] [48] . In 35/44 patients, the overall CIOMS causality grading remained unchanged whether or not age as a risk factor was included in the CIOMS scale scoring (Table  6 ). Deletion of age as a risk factor reduced the overall CIOMS grading by one causality level in 9/44 patients, i.e., from unlikely to excluded in 5 cases (patients 1, 3, 15, 42, 43), from highly probable to probable in 1 case (patient 23), and from probable to possible in 3 cases (patients 9, 25, 34). Therefore, within this cohort the risk factor age upgraded the causality levels only marginally, which appears to have no clinical relevance. Overall, age as a risk factor has a limited impact on the final causality gradings by the CIOMS scale.
Risk factors are not considered and/or not scored by various other methods [4, 24, 49, 50] , including the DILIN method [49, 50] . Conversely, the international DILI Expert Group also accepts the risk factors defined in the CI-OMS scale, with modified specifications and limitations, if risk factors for hepatotoxicity are present in addition to those listed in the CIOMS algorithm [14] .
Concomitant drug(s) and herbs(s)
Concomitant drugs and herbs are individually assessed for temporal association and hepatotoxic potency (Tables  1 and 2 ). For reasons of comparison and transparency, each comedicated drug or herb requires a separate analysis by the complete CIOMS scale. This is feasible and easily tabulated (Table 7) [30, 47, 48] . In patients with multiple drug or herb intakes, causality should be attributed primarily to the product with the highest score.
Search for non drug/herb causes
In this section, the CIOMS scale considers the clinically most relevant alternative causes (Tables 1 and 2 ). There is no difference in alternative causes made between the two types of liver injury, avoiding the need of subsequent reassessment, if the laboratory based typology changes during the clinical course [45] . Complications of underlying disease(s) are exemplified, such as sepsis, autoimmune hepatitis, chronic hepatitis B or C, primary biliary cirrhosis and sclerosing cholangitis and genetic liver diseases (Tables 1 and 2 ), in accordance with recent suggestions [45] . Other rare alternative causes are included in a checklist of differential diagnoses as a reminder for the clinician in case of unclear clinical diagnosis (Table 3 ) [24] . To improve its performance when used as an investigational tool, criteria for competing liver injury causes have been proposed for the CIOMS scale [14, 29, 44, 45, 49, 50] 
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unknown at the time of compilation [21] but specified in the updated CIOMS scale; also included and specified were infections by hepatitis E virus (HEV) and varicella zoster virus (VZV) ( Tables 1 and 2 ) [24] . Specific diagnostic criteria include polymerase chain reaction detection and titer changes of the respective antibodies (IgM, IgG) for CMV, EBV, HEV, HSV and VZV infections. Hepatobiliary sonography was supplemented by color Doppler sonography, including assessments of the liver vessels, endosonography, computed tomography (CT) and magnetic resonance cholangiography (MRC), if these tests were indicated clinically (Tables 1 and 2 ). For comparison and method validation, causality has been evaluated in 101 hepatotoxicity cases by both the original and updated CIOMS scales, with identical causality results published in 6 studies [32, 33, [36] [37] [38] [39] . Therefore, the updated CIOMS scale was validated and there is no need for further validation of the updated CIOMS scale versus the original CIOMS scale.
Previous information on hepatotoxicity of the drug/herb
Hepatotoxicity listed in the product information sheet must be checked; in addition, a quick literature search in PubMed will be sufficient to determine whether the observed reaction has been published before. Appropriate information may also be obtained from the NIH LiverTox database [44, 45] .
Response to unintentional readministration
To classify an unintentional reexposure test as positive, few criteria are required (Tables 1 and 2 ), as specified (Table 4) [21, 22, 24, 26, 27] . Although reexposure is an important domain, probable causality gradings with the CIOMS scale are achievable even in the absence of a reexposure (Table  7 ) [12, 17, [30] [31] [32] 37] .
Scoring system
Each item of the CIOMS scale receives an individual score and the sum of the individual scores provides the final score for the patient (Tables 1 and 2 ). With +14 down to -9 points, there is a wide range of the final scores, leading to the following causality levels: ≤ 0 points, excluded causality; 1-2, unlikely; 3-5, possible; 6-8, probable; and ≥ 9, highly probable (Tables 1 and 2 ) [21] . Sensitivity, specificity and predictive value Cases with positive reexposure tests were proposed for validation of the CIOMS scale and used as gold standard [22] . Articles from two databanks were compiled with liver injury confirmed by a positive rechallenge. The mandatory information for inclusion in this series contained the type of liver injury, time interval between administration of the drug and occurrence of the reaction, and results of the positive response to readministration of the drug, in accordance with the conclusions of the International Consensus Meeting on drug induced liver injuries. For the final validation, 49 cases and 28 controls were assessed, as described in detail [22] . Most importantly, the discriminative power of the score was quantified in terms of sensitivity, specificity and predictive values. The cut off point was offset to maximize the combined sensitivity and specificity. Using +5 points as the cut off, sensitivity was 86%, specificity 89%, positive predictive value 93%, and negative predictive value 78% for the CIOMS causality assessment. In another study with 81 cases and 46 controls, sensitivity was 78% and specificity 100% for the CIOMS scale [51] , confirming the validation of the CIOMS scale.
The interrater reliability of CIOMS assessment was good by one group [52] but mediocre by the DILIN group [49] . In the latter report, however, 40 cases going back to 1994 were studied. Uncertainties arose from numerous missing, incomplete or outdated medical reports and charts, especially for older cases. In particular, there were high rates (28%) of preexisting liver diseases like chronic hepatitis C virus infection, hemochromatosis and unspecified cirrhosis. Liver sonography was reported in 26/40 cases and found abnormal in 15/26 (58%). These data were nevertheless described as ''best-case scenario'' [49] . Considering these limitations and numerous confounding variables, poor case data quality likely results in mediocre assessment quality, including low interrater reliability [49] . Moreover, problematic data presentation by the principal assessor to external reviewers may have influenced the results as the external reviewers received only a subset of the case report forms and had no access to the original data of the cases [49] . Of interest, no proof has been provided that an expert group opinion improves the CIOMS assessment evaluation, at least according to recent comments and studies [11, 49] . In another study comparing the CIOMS scale with the DILIN method, there was considerable interobserver variability in both methods [50] .
Usage frequency
The CIOMS scale for hepatotoxicity assessment in its original or updated form [4, 5, 10, 14, 23, 24, 28, 29] has been extensively used in epidemiological studies, clinical trials, case reports, case series, regulatory analyses and genotyping studies [4] . Additional efforts are still needed to reevaluate causality in most HILI reports for 60 different herbs and herbal products [53] . CIOMS based results were published by the DILIN group [49, 50] and by the European Medicines Agency (EMA) [54] . Individual studies [10, 16, 55, 56] , the NIH LiverTox [44, 45] , the international DILI Expert Working Group [14] , the Spanish Group for the Study of DrugInduced Liver Disease [29] , and the Hong Kong HerbInduced Liver Injury Network (HK-HILIN) [57] provided further support for the CIOMS scale.
Among various causality assessment methods, the original and updated CIOMS scales were the preferred tools in cases of DILI [28] and HILI (Table 8 ) [5] , seen for 573 cases from 23 HILI reports evaluating alternative causes [12, 32, 34, [36] [37] [38] [39] 42, 43, 47, 48, 54, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] . Transparency CIOMS based assessments should be reported or published as an original data set suitable for subsequent and independent assessments, rather than as final scores and corresponding causality levels, to improve data transparency. Scientists, editors and reviewers should strive to obtain appropriate CIOMS based details for all DILI and HILI case reports. This can easily be achieved since the CIOMS scale provides all items in tabulated form for each individual case (Tables 1, 2 and 7) . These forms may be communicated as a spontaneous report to regulatory agencies and expert panels or presented for publication to scientific journals as a case report [24, 30, 31] or case series [12, 24, 32] . This tabulation is a good basis for further regulatory or scientific assessments and discussions. For regulatory and expert based assessments, there is no need for other causality assessment algorithms to be used subsequently since CIOMS based data are also amenable to regulatory and expert panel evaluations.
Comparison to precursor scales
The CIOMS scale resulted from intensive expert discussions [21] , integrating medical progress and improving the initial qualitative RUCAM [26] and the qualitative CIOMS method [27] . The qualitative RUCAM represented the first objective attempt to assess causality in drug induced liver injury and considered some characteristic features of liver injury, but it had a qualitative rather than a quantitative approach [26] . As an improved version of the qualitative RUCAM [26] , the qualitative CIOMS method differentiated the hepatocellular, the cholestatic and the mixed type of liver injury [27] . However, both the qualitative RUCAM [26] and the qualitative CIOMS method [27] were not quantitative, as opposed to the current quantitative CIOMS scale [21] that is now the preferred tool [24] .
Other liver specific methods
The scale of Maria and Victorino (MV) [68] was developed to improve upon the CIOMS scale by deleting laboratory items and adding clinical elements, along with simplifying and changing the relative weight of elements in their algorithm [23, 44, 45] . No data are available for specificity, sensitivity, positive and negative predictive values for the MV scale [68] . Compared to the original CIOMS scale [21] , the MV scale [68] showed shortcomings and the results are not equivalent, causing major concern [10, 14, 23, 24, 29, 44, 45, [69] [70] [71] . This may explain why the MV scale was used in a few DILI studies [1, 72, 73] , but not in 38 other publications of DILI cases [28] or in 23 publications of HILI cases [5] . The MV scale is not commonly recommended for assessing causality in assumed DILI and HILI cases and is certainly no substitute for the CIOMS scale [24] . The TTK scale [25] , named for the first three authors Takikawa, Takamori, Kumagi et al [74] , is a modification of the CIOMS scale [21] with different evaluations of the chronology, exclusion of comedication, inclusion of the drug lymphocyte stimulation test (DLST) and of eosinophilia in their assessment system [74, 75] . The TTK scale is widely used in Japan [74] , as recently reviewed [75] . In other countries, this scale is not or rarely [59] Kava 20 Teschke et al [60] Kava 36 Stickel et al [61] Kava 80 Schmidt et al [62] Greater Celandine 23 BfArM [63] Black cohosh 31 EMA [54] Herbalife products 12 Elinav et al [64] Herbalife products 12 Schoepfer et al [65] Kava 26 Teschke et al [12] Black cohosh 30 Mahady et al [42] Green tea 34 Sarma et al [43] Black cohosh 4 Teschke et al [47] Black cohosh 9 Teschke et al [48] Kava 31 Teschke [34] Hydroxycut 17 Fong et al [66] Black cohosh 22 Teschke et al [36] Greater Celandine 22 Teschke et al [37] Herbalife products 20 Manso et al [67] Various herbs 45 Chau et al [57] Greater Celandine 21 Teschke et al [32] Pelargonium sidoides 15 Teschke et al [38] Pelargonium sidoides 13 Teschke et al [39] Sum ( The data are derived from a study evaluating alternative causes in suspected HILI cases (n = 573) comprising the study cohort [5] . For the 275 CIOMS cases, causality assessment was performed with the updated CIOMS scale the original CIOMS scale, or both. considered [5, 10, 14, 24, 28, 29, 44, 45, 76] . Limited access and lack of standardization have prevented general clinical use of the DLST and consequently TTK scale applications outside Japan [29] ; this may be due to methodological difficulties with false positive and false negative cases in the DLST [25, 75] . For clinicians, the TTK scale cannot replace the CIOMS scale [25] . The DILIN method provided by the DILIN group requires an expert panel [3, 6, 11, 24, 44, 45, 49, 50, 77, 78] , in contrast to the CIOMS scale [21, 24] . Consequently, the DILIN method is of limited availability to physicians in need of early results for therapeutic decisions [24] . In particular, the DILIN method is not an appropriate substitute for the CIOMS scale, nor are other expert panel based approaches [24] . This includes the novel Causality Assessnovel Causality Assessment Tool (CAT) specifically designed for herbs and dietary supplements (HDS), which was presented as an abstract [15] . As opposed to CIOMS based results with transparent data presentation (Table 7 ) [12, 30, 32, [36] [37] [38] [39] 47, 48, 71] , publications based on the DILIN method lack transparency for individual cases regarding assessed and scored items since only final causality levels are published without details and thereby open for discussions, not allowing valid conclusions [3, 6, 11, 49, 50, 77, 78] . The DILIN method also lacks data on specificity, sensitivity and predictive values, as an expert opinion based method no items can be validated. Individual weighing and scoring of items remain undisclosed and undiscussed, hampering thorough analysis of assessment results by the DILIN method.
Liver unspecific methods
In contrast to the liver specific core elements of the original and updated CIOMS scale (Tables 1 and 2) [4, [21] [22] [23] [24] , numerous causality algorithms are liver unspecific [4, 24, 76, 79, 80] , including the Naranjo scale [81] , the World Health Organization (WHO) global introspection method as the WHO method in short [82] , and the KL method of Karg and Lasagna [83] . Particularly intensive discussions focused on the Naranjo scale [4, 24, 25, [84] [85] [86] [87] , the WHO method [4, 24, 84, 87] , and the KL method [24, 25] . All these methods are obsolete for causality assessment of assumed hepatotoxicity as they lack liver specificity and do not consider hepatotoxicity characteristics.
WEAKNESSES
Retrospective use
Retrospective analysis of case data is problematic and may require some assistance evaluating the CIOMS items [14, 44, 45] ; unselected and sometimes undefined, low quality data have to be adapted into a structured algorithm like the CIOMS scale. Therefore, physicians should prospectively use the CIOMS scale, which then may provide complete case data (Table 7 ) [30] .
Dechallenge criteria
Missing ALT dechallenge data are factored as 0 points given (Table 1) ; this condition has been interpreted as a limitation of the CIOMS scale [14] . Retrospective studies commonly lack dechallenge results [6, 12, 32, [34] [35] [36] [37] [38] [39] which are included in prospective evaluations (Table 7 ) [30] . CIOMS performs inaccurately in acute liver failure and liver transplantation if liver values are not available within 30 d after cessation of the incriminated drug or herb. Under these circumstances, 0 but not negative points are credited due to lacking ALT data (Tables 1 and 2 ).
Risk factors
The CIOMS scale includes only the risk factors of alcohol and age ≥ 55 years [21] . Diabetes, metabolic syndrome, sex, ethnicity and body mass index [14] , as well as genetic predisposition [29] , are also proposed as potential risk factors; the lack of inclusion in the CIOMS scale has been considered as a limitation [14, 29] . However, these factors have not been validated as risk factors; their inclusion into the CIOMS scale requires evidence as independent contributors and a subsequent new validation.
Alternative causes
It may be argued that rare alternative causes were not listed in the CIOMS scale (Tables 1 and 2 ) but this shortcoming was compensated for by the checklist for numerous rare liver diseases as a reminder for the clinician (Table 3 ) [24] .
Previous information on hepatotoxicity of drug/herb
Safety labels are available for both synthetic and herbal drugs but rarely for other herbal products. This shortcoming of the CIOMS scale may be compensated by a thorough search for prior publications of hepatotoxicity by herbal products; published reports provide an even higher scoring than information obtained only from safety labels.
CONCLUSION
The major strength of the CIOMS is its potential as a standard scale for DILI and HILI causality assessment by attending physicians, regulatory agencies, expert panels and the scientific community. Other advantages include its liver specificity and its validation for hepatotoxicity cases, with excellent sensitivity, specificity and predictive validity based on results obtained from cases with a positive reexposure test. This scale will allow the physician treating patients with suspected DILI and HILI an early preliminary result of the likelihood, facilitates timely and prospective collection of all relevant data required for a subsequent valid causality assessment, does not require an expert panel, and has the option of subsequent refinement by regulatory agencies, expert panels and the scientific community. With the CIOMS scale, an identical causality assessment algorithm can used by all evaluating parties, which facilitates the overall procedure of causality association. Minor weaknesses of the CIOMS scale include the limited exclusion of alternative causes and the handling of poor case data in retrospectively rather than prospectively assessed cases.
